| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 2,290 | 1,630 | 1,070 | 1,210 | 1,180 |
| Sales Growth | +40.49% | +52.34% | -11.57% | +2.54% | +13.46% |
| Net Income | -18,630 | -18,820 | -14,250 | -11,390 | -7,540 |
| Net Income Growth | +1.01% | -32.07% | -25.11% | -51.06% | -8.96% |
Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.
Fiscal Year End Date: 12/31